Can a new drug that reduces a stress hormone make one of the standard drugs given for advanced pancreatic cancer more effective?
The clinical trial uses this new drug with nab-paclitaxel, to see if the combination can delay the progress of the disease and extend the life of advanced pancreatic cancer patients.
Changing Levels of a Stress Hormone
Cortisol is a hormone that regulates the body’s stress response and suppresses the normal process of cell death. Relacorilant is a new drug that is an antagonist of cortisol receptors, blocking their action. It has shown potential antitumor properties. Nab-paclitaxel inhibits cell division and promotes cell death.
Participating in this Trial
To qualify for this trial patients must have metastatic pancreatic cancer and have undergone two previous types of treatment, including with gemcitabine and fluoropyrimidine-based drugs (capecitabine or fluorouracil); prior treatment with nab-paclitaxel is also permitted. All participants will receive the treatment combination being studied. Researchers are looking at the effectiveness of the combination and how it affects overall survival.
We encourage you to consult your physicians for clinical trials that may be right for you. The website ClinicalTrials.gov provides more details about this trial as well as many others. You can visit the EmergingMed Trial Finder for a list of all active pancreatic cancer clinical trials.
This trial has been terminated for not meeting its response rate.